The ability to extend the survival period of cancer patients is a ray of hope for life, and with the continuous breakthroughs in treatment modalities and medications, the dream can be realized! Currently, immunocell therapy has become the fourth type of cancer treatment, but the cost to the patient is not expensive, and the effectiveness is highly challenged, and even have to go out of the country to seek. Now, the domestic biomedical industry and the accumulation of 22 kinds of cancer, more than 100,000 cancer patients treatment experience of the Japanese company technology cooperation "dendritic cell cancer vaccine" therapy, the future of Taiwan's cancer patients will be able to hope that the clinical through this therapy, can play the role of poisonous cancer cells to inhibit the tumor enlargement or cancer cell proliferation, will be the "cold tumors into hot tumors," to play the role of poisonous cancer cells!
XinPin Biomedical announced that it has partnered with the Tella Group, a publicly traded company in Japan, to license the patented technologies of "DC (Dendritic Cell) Cancer Vaccine" and "Super NK (Natural Killer) Cells", two important immune cell preparations.Domestic biomedical industry from the introduction of Japan to authorize two immune cell preparation patent technology
Following the Ministry of Health and Welfare to liberalize the use of immune cells for a number of cancer clinical treatments, Xinpin Biomedical announced that it has cooperated with the Japanese listed company, Tella Group, to authorize two important immune cell preparation patents such as the DC (dendritic cell) cancer vaccine and the Super NK (Natural Killer) cells. Cells" and "Super NK (Natural Killer) Cells", which are two important patented immune cell preparation technologies. This will allow clinicians and cancer patients to benefit from Japan's 15 years of experience in immune cell culture technology in Taiwan.
Pan Jun-You, Chairman of Xinpin Biomedical, pointed out that the "DC (dendritic cell) cancer vaccine" therapy introduced into the country by Xinpin was developed by the University of Tokyo. In Japan, there are 22 types of cancers, more than 11,000 cancer patients have experience in using the therapy, including pancreatic cancer, which is relatively unsatisfactory to the effectiveness of the existing conventional anticancer treatments, as well as colorectal cancer, which is the most common new cancer in the country, and lung cancer, which is the leading cancer in terms of the number of deaths.
What is a dendritic cell cancer vaccine?
Professor Naohide Yamashita, Professor Emeritus at the University of Tokyo, said that dendritic cells (or DCs) are immune cells found in the human body and are derived primarily from hematopoietic stem cells in the human bone marrow. Dendritic cells are like the commander of the body's defense system, with the ability to phagocytose and present antigens themselves. When dendritic cells recognize foreign pathogens or cancer cells, they will begin to phagocytose and break down these cancer cells into small fragments, and then present the antigens of the cancer cells on the surface of the dendritic cells to train the T-cells to recognize these cancer cells, so as to achieve the goal of using the immune cells (T-cells) to carry out an accurate and effective attack against the cancer cells.
tella President Yuichiro Yazaki pointed out that the dendritic cell vaccine is first obtained from the patient's blood mononuclear spheres, cultured into dendritic cells in vitro, and then added with protein fragments with the characteristics of the target cancer, also known as cancer cell antigens, so that the dendritic cells to memorize the characteristics of the cancer cells, and then injected into the patient's body, to induce immune response against the cancer cells. The dendritic cell vaccine enhances the body's immune response to the cancer cells, and is often used in conjunction with existing treatments such as surgery, radiotherapy, and targeted therapies to assist the body in removing the remaining cancer cells in the body.
Professor Lai Kee-ming, Director of the Cancer Center at Wan Fang Hospital, noted that the future of immune cell therapy can be envisioned, and that patients are looking forward to it.
Why Dendritic Cell Vaccine Therapy Helps Turn "Cold Tumors into Hot Tumors?
The so-called "cold tumors" and "hot tumors" actually refer to immunogenic tumors (hot tumors) and non-immunogenic tumors (cold tumors). Cold tumors are tumors that have no or very few immune cells in the tumor tissues, and in the past, the efficacy of immunotherapy used alone in these patients was not good. Dendritic Cell Vaccine Therapy (DCVT) helps to increase the number of immune cells and activate the immune checkpoint inhibitors, which reduces the chance of the tumor cells to have a "death grip" with the immune cells, and then it can play a role in killing the cancer cells. The checkpoint inhibitor removes the braking effect of the tumor on the immune cells, and then these immune cells can easily blow the burning flame towards the base occupied by the cancer cells, and thus have a therapeutic effect on the "hot tumor".
The "dendritic cell vaccine therapy", which utilizes autologous immune cells to attack cancer cells, will be applied for as soon as possible in the future, and is expected to be available for clinical use in Taiwan by the end of the year at the earliest. Professor Lai Ji-Ming, executive director of the Taiwan Cancer Foundation and director of the Cancer Center at Wan Fang Hospital, pointed out that the NK cells provided by immune cell therapy are like various armed forces that have gone through *** to form a sea of people to attack cancer cells. If combined with immune checking inhibitors, it is equal to the immune cells that have been stopped and liberated, and once again get the help of immune cells, which can greatly strengthen the effect of immunotherapy.
After the implementation of the special administrative measures, as long as through the orthodox medical institutions and specialized physicians, to formulate treatment plans, to submit applications for clinical application, and to have qualified culture and expansion equipment of the GTP laboratories to manufacture the cell products used, there will be the opportunity to pass the application, the treatment of cancer, we can foresee the future of the immunocellular therapy, and make the patients full of expectations.